汉森制药(002412) - 2015 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2015 was ¥171,079,990.02, a decrease of 1.86% compared to ¥174,323,128.95 in the same period last year[4] - The net profit attributable to shareholders was ¥28,622,839.74, down 10.99% from ¥32,157,600.58 year-on-year[4] - The basic earnings per share decreased by 10.96% to ¥0.0967 from ¥0.1086 in the same period last year[4] - The net profit attributable to shareholders for the first half of 2015 is expected to range from 4,766.87 to 6,449.29 million CNY, reflecting a change of -15.00% to 15.00% compared to the same period in 2014[16] - The net profit for the first half of 2014 was 5,608.08 million CNY, indicating a potential decline in performance for 2015[16] - Increased financial expenses and fixed asset depreciation are anticipated to contribute to the expected decline in operating performance[16] Cash Flow - The net cash flow from operating activities was negative at -¥8,830,601.99, a decline of 179.53% compared to ¥11,103,947.00 in the previous year[4] - The cash flow from investing activities decreased by 76.76%, down by ¥21,053,993.73, primarily due to a significant reduction in cash recovered from investments[12] - The cash flow from financing activities increased by 30.44%, up by ¥252,594.78, mainly due to a decrease in cash paid for dividends and interest[12] Assets and Shareholders - Total assets at the end of the reporting period were ¥1,364,958,056.30, a slight decrease of 0.21% from ¥1,367,771,693.92 at the end of the previous year[4] - The net assets attributable to shareholders increased by 2.56% to ¥1,148,153,380.26 from ¥1,119,530,540.52 at the end of the previous year[4] - The company had a total of 17,035 common shareholders at the end of the reporting period[7] Non-Operating Income - The company reported a 41.96% decrease in non-operating income, down by ¥266,133.12 due to reduced government subsidies[12]